Previous 10 | Next 10 |
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...
Bank of America upgraded the Israeli drugmaker Teva Pharmaceutical (NYSE:TEVA) to Neutral from Underperform on Tuesday, citing a shift in the attention to the company’s product portfolio following a potential countrywide opioid settlement. Teva (TEVA) ADRs have added ~3% in t...
One way to look at the immuno-oncology landscape over the last few years has been to think of it as The Quest for Synergy. And while there are indeed plenty of indications and plenty of targets yet to be explored, with plenty of antibodies for each, etc., what we've been seeing are so...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q1 earnings call. For further details see: Organon & Co. 2022 Q1 - Results - Earnings Call Presentation
Organon & Co (OGN) Q1 2022 Earnings Conference Call May 05, 2022, 08:30 ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Terence Flynn - Morgan Stanley...
Organon (NYSE:OGN), the Merck (MRK) spinoff focused on women’s health and biosimilars, is trading ~4% higher in the pre-market Thursday after reporting better than expected financials for Q1 2022 thanks to the outperformance of its established brands segment. After back-...
Organon press release (NYSE:OGN): Q1 Non-GAAP EPS of $1.65 beats by $0.35. Revenue of $1.57B (+4.0% Y/Y) beats by $50M. Board of Directors declares quarterly dividend of $0.28 per share Full year 2022 financial guidance ranges affirmed Revenue of $6.1B-$6.4B vs. $6.26B consensus. For furthe...
First quarter 2022 revenue of $1,567 million Net income from continuing operations of $348 million, or $1.36 per diluted share; Adjusted net income from continuing operations of $420 million, or $1.65 per diluted share Adjusted EBITDA of $647 million Board of Directors dec...
Organon (NYSE:OGN) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $1.30 and the consensus Revenue Estimate is $1.52B (+0.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue es...
Goldman Sachs boosted its forecast for dividend growth this year, with earnings growth the primary driver. The equity team now sees dividend growth of +10% for 2022. S&P 500 (SP500) (SPY) dividends per shares "grew by +11% year/year in 1Q 2022," strategist David Kostin wrote in a note. "I...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...